Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

44.93
+0.28000.63%
Post-market: 45.240.3100+0.69%19:00 EDT
Volume:1.98M
Turnover:89.42M
Market Cap:11.41B
PE:16.16
High:45.54
Open:44.72
Low:44.72
Close:44.65
52wk High:49.62
52wk Low:33.76
Shares:254.01M
Float Shares:206.00M
Volume Ratio:0.71
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.78
ROE:35.53%
ROA:19.27%
PB:5.28
PE(LYR):16.16

Loading ...

Earning Preview: Exelixis Q1 revenue is expected to increase by 21.51%, and institutional views are cautious with Hold calls dominant

Earnings Agent
·
Yesterday

Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL

TIPRANKS
·
Apr 24

Does Exelixis (EXEL) Gain Quiet Competitive Leverage From a Rival’s Kidney Cancer Setback?

Simply Wall St.
·
Apr 23

The Tactical Trio Blueprint For Solid Balance Sheet And Fundamentals

Simply Wall St.
·
Apr 22

Exelixis schedules quarterly results release and conference call

Reuters
·
Apr 22

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Apr 20

A Look At Exelixis (EXEL) Valuation As CABOMETYX Growth And Trial Outlook Shape Expectations

Simply Wall St.
·
Apr 17

Exelixis publishes 2025 annual report

Reuters
·
Apr 16

Exelixis announces annual shareholder meeting

Reuters
·
Apr 16

Wells Fargo Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Apr 14

Exelixis (EXEL) Gets a Hold from RBC Capital

TIPRANKS
·
Apr 09

Wells Fargo Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Apr 02

Genmab names Margarida Duarte general manager for Europe and emerging markets

Reuters
·
Apr 01

Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)

TIPRANKS
·
Mar 25

Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts

Simply Wall St.
·
Mar 13

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)

TIPRANKS
·
Mar 09

A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline

Simply Wall St.
·
Mar 05

Exelixis Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Mar 03

Exelixis price target lowered to $43 from $46 at RBC Capital

TIPRANKS
·
Mar 02

RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating

MT Newswires Live
·
Mar 02